Biosolutions
Sales for 2025 at Biosolutions were down 3.9 percent, falling to €360.4 million (2024: €374.9 million) due to lower volumes of established products and exchange-rate effects. Sales in the division showed positive development in Europe, and negative development in the Americas and Asia.
Due to the sales effects, lower project business relating to contract manufacturing, and low plant-utilization rates, EBITDA amounted to €20.7 million (2024: €35.1 million), which was well below the prior-year figure. The EBITDA margin was 5.7 percent (2024: 9.4 percent). EBIT was, moreover, impacted by approx. €90 million incurred by an impairment of goodwill associated with the acquisition of ADL Biopharma.
Capital spending fell compared to the previous year, down from €49.3 million in 2024 to €26.3 million in 2025. The division invested in technical equipment in the reporting period, including an automated packaging system and laboratory equipment. The number of employees as of December 31, 2025, totaled 1,127 (December 31, 2024: 1,189 employees).
€ million |
|
2025 |
|
2024 |
|
2023 |
|
2022 |
|
2021 |
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Total sales |
|
360.4 |
|
374.9 |
|
337.2 |
|
331.1 |
|
296.4 |
EBITDA |
|
20.7 |
|
35.1 |
|
6.5 |
|
16.7 |
|
38.6 |
EBITDA margin (%) |
|
5.7 |
|
9.4 |
|
1.9 |
|
5.0 |
|
13.0 |
EBIT |
|
-122.6 |
|
-17.1 |
|
-20.1 |
|
-4.7 |
|
20.7 |
Capital expenditures |
|
26.3 |
|
49.3 |
|
155.5 |
|
102.6 |
|
33.5 |
R&D expenses |
|
7.5 |
|
9.6 |
|
5.5 |
|
4.8 |
|
5.6 |
Employees (number as of Dec. 31) |
|
1,127 |
|
1,189 |
|
1,191 |
|
835 |
|
751 |